Apixaban Enhances Vasodilatation Mediated by Protease-Activated Receptor 2 in Isolated Rat Arteries

EPAS1/HIF-2 alpha-mediated downregulation of tissue factor pathway inhibitor leads to a pro-thrombotic potential in endothelial cells

(2016) Benedicte Stavik et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Apixaban: A Review in Venous Thromboembolism

(2016) Sarah L. Greig et al.   DRUGS

Contributions of protein kinases and β-arrestin to termination of protease-activated receptor 2 signaling

(2016) Seung-Ryoung Jung et al.   JOURNAL OF GENERAL PHYSIOLOGY

What are they waiting for?—Tethered agonism in G protein-coupled receptors

(2016) Torsten Schöneberg et al.   PHARMACOLOGICAL RESEARCH

Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway

(2015) Giovanni Giurdanella et al.   BIOCHEMICAL PHARMACOLOGY

Pharmacotherapy with oral Xa inhibitors for venous thromboembolism

(2015) Thomas Vanassche et al.   EXPERT OPINION ON PHARMACOTHERAPY

Regulation of vascular tone in rabbit ophthalmic artery: Cross talk of endogenous and exogenous gas mediators

(2014) Salvatore Salomone et al.   BIOCHEMICAL PHARMACOLOGY

New insights into the spatiotemporal localization of prothrombinase in vivo

(2014) L. Ivanciu et al.   BLOOD

Transactivation of the PAR1-PAR2 Heterodimer by Thrombin Elicits β-Arrestin-mediated Endosomal Signaling

(2013) Huilan Lin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A new paradigm shift in antithrombotic therapy

(2013) Anita Pudusseri et al.   Frontiers in Pharmacology

Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110)

(2011) JY Suen et al.   BRITISH JOURNAL OF PHARMACOLOGY

Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice

(2011) Giovanni Li Volti et al.   Cardiovascular Diabetology

Determinants of the specificity of protease-activated receptors 1 and 2 signaling by factor Xa and thrombin

(2011) Soumendra Rana et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor

(2011) Pancras C. Wong et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Factor X/Xa Elicits Protective Signaling Responses in Endothelial Cells Directly via PAR-2 and Indirectly via Endothelial Protein C Receptor-dependent Recruitment of PAR-1

(2010) Jong-Sup Bae et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effect of the Direct Factor Xa Inhibitor Apixaban in Rat Models of Thrombosis and Hemostasis

(2010) William A Schumacher et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma

(2010) Joseph M. Luettgen et al.   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Apixaban, an oral, direct and highly selective factor Xa inhibitor:in vitro, antithrombotic and antihemostatic studies

(2008) P. C. WONG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Inhibition of Cerebral Vasoconstriction by Dantrolene and Nimodipine

(2008) Salvatore Salomone et al.   Neurocritical Care

Factor Xa: at the crossroads between coagulation and signaling in physiology and disease

(2008) Keren Borensztajn et al.   TRENDS IN MOLECULAR MEDICINE